Comparative assessment of budesonide-MMX and mesalamine in active, mild-to-moderate ulcerative colitis: a systematic review and network meta-analysis.
Fiche publication
Date publication
juillet 2019
Journal
British journal of clinical pharmacology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Bonovas S, Nikolopoulos GK, Piovani D, González-Lorenzo M, Pantavou K, Lytras T, Peyrin-Biroulet L, Danese S
Lien Pubmed
Résumé
The comparative efficacy, safety and tolerability of budesonide-MMX and oral mesalamine in active, mild-to-moderate ulcerative colitis (UC) are unclear. We conducted a network meta-analysis to fill this evidence gap.
Mots clés
budesonide-MMX, mesalamine, ulcerative colitis
Référence
Br J Clin Pharmacol. 2019 Jul 3;: